These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37959261)

  • 21. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.
    Brandse JF; Vos LM; Jansen J; Schakel T; Ponsioen CI; van den Brink GR; D'Haens GR; Löwenberg M
    J Crohns Colitis; 2015 Nov; 9(11):973-81. PubMed ID: 26116557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct Association of Serum Vitamin D Concentration with Disease Activity and Trough Levels of Infliximab and Adalimumab during Inflammatory Bowel Disease Treatment.
    Mechie NC; Mavropoulou E; Ellenrieder V; Kunsch S; Cameron S; Amanzada A
    Digestion; 2020; 101(6):761-770. PubMed ID: 31536991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis.
    Stevens TW; Gecse K; Turner JR; de Hertogh G; Rubin DT; D'Haens GR
    Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2333-2342. PubMed ID: 32801008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers.
    McDonald C; Kerr H; Gibbons E; Lukose T; Cheriyan D; Harewood G; Patchett S; O'Toole A; Kelly O; Boland K
    Inflamm Bowel Dis; 2024 Mar; 30(3):423-428. PubMed ID: 37158577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients.
    Choi SY; Choi YO; Choe YH; Kang B
    J Korean Med Sci; 2020 Apr; 35(16):e114. PubMed ID: 32329259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histological Indices and Risk of Recurrence in Crohn's Disease: A Retrospective Study of a Cohort of Patients in Endoscopic Remission.
    Marion L; Amélie B; Zoubir D; Guillaume C; Elise MS; Hedia B; Margaux LS; Aude M; Camille BR
    Inflamm Bowel Dis; 2022 Sep; 28(9):1395-1404. PubMed ID: 35429159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.
    Imaeda H; Takahashi K; Fujimoto T; Bamba S; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
    J Gastroenterol; 2014 Jan; 49(1):100-9. PubMed ID: 23575576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, quality-of-life and economic outcomes.
    Pandey A; Achrafie L; Kodjamanova P; Tencer T; Kumar J
    Curr Med Res Opin; 2022 Sep; 38(9):1531-1541. PubMed ID: 35608153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease.
    Löwenberg M; Vermeire S; Mostafavi N; Hoentjen F; Franchimont D; Bossuyt P; Hindryckx P; Rispens T; de Vries A; van der Woude CJ; Berends S; Ambarus CA; Mathot R; Clasquin E; Baert F; D'Haens G
    Gastroenterology; 2019 Oct; 157(4):997-1006.e6. PubMed ID: 31175865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn's Disease.
    Wong ECL; Yusuf A; Pokryszka J; Dulai PS; Colombel JF; Marshall JK; Reinisch W; Narula N
    Inflamm Bowel Dis; 2023 Jun; 29(6):875-882. PubMed ID: 35880680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up.
    Chen DY; Chen YM; Hsieh TY; Hung WT; Hsieh CW; Chen HH; Tang KT; Lan JL
    Rheumatology (Oxford); 2016 Jan; 55(1):143-8. PubMed ID: 26324949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis.
    Ponce-Bobadilla AV; Stodtmann S; Chen MJ; Winzenborg I; Mensing S; Blaes J; Haslberger T; Laplanche L; Dreher I; Mostafa NM
    Clin Pharmacokinet; 2023 Apr; 62(4):623-634. PubMed ID: 36905528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
    Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease.
    Takenaka K; Kawamoto A; Hibiya S; Suzuki K; Fujii T; Motobayashi M; Shimizu H; Nagahori M; Saito E; Okamoto R; Watanabe M; Ohtsuka K
    Aliment Pharmacol Ther; 2021 Oct; 54(8):1052-1060. PubMed ID: 34323301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis.
    Papamichael K; Rakowsky S; Rivera C; Cheifetz AS; Osterman MT
    Aliment Pharmacol Ther; 2018 Feb; 47(4):478-484. PubMed ID: 29210094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing.
    Chang J; Leong RW; Wasinger VC; Ip M; Yang M; Phan TG
    Gastroenterology; 2017 Sep; 153(3):723-731.e1. PubMed ID: 28601482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn's Disease: A Cross-Sectional Multicentric Latin American Study.
    de Souza LR; Magro DO; Teixeira FV; Parra RS; Miranda EF; Féres O; Saad-Hossne R; Soares Prates Herrerias G; Nisihara RM; Coy CSR; Sassaki LY; Kotze PG
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The diagnostic and evaluation value of plasma interleukin 9 in the mucosal healing in patients with inflammatory bowel disease treated with biological agents].
    Ye YL; Hu T; Xu LJ; Zhang LP; Yin J; Yu Q; Pang Z
    Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1483-1489. PubMed ID: 37198111
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.